<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32037</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Pregravid preparation of diabetic women</article-title><trans-title-group xml:lang="ru"><trans-title>Прегравидарная подготовка женщин, больных сахарных диабетом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grigoryan</surname><given-names>O R</given-names></name><name xml:lang="ru"><surname>Григорян</surname><given-names>О Р</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Volevodz</surname><given-names>N N</given-names></name><name xml:lang="ru"><surname>Волеводз</surname><given-names>Н Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Andreeva</surname><given-names>E N</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>Е Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Эндокринологический научный центр Минздрава России, Москва</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="ru">Первый МГМУ им. И.М. Сеченова Минздрава России, Москва</institution></aff><aff><institution xml:lang="en"></institution></aff></aff-alternatives><aff id="aff3"><institution>Первый МГМУ им. И.М. Сеченова Минздрава России, Москва</institution></aff><aff id="aff4"><institution>Эндокринологический научный центр Минздрава России, Москва</institution></aff><pub-date date-type="pub" iso-8601-date="2016-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2016</year></pub-date><volume>88</volume><issue>7</issue><issue-title xml:lang="en">VOL 88, NO7 ()</issue-title><issue-title xml:lang="ru">ТОМ 88, №7 (2016)</issue-title><fpage>114</fpage><lpage>119</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32037">https://ter-arkhiv.ru/0040-3660/article/view/32037</self-uri><abstract xml:lang="en"><p>Pregnancy in women with type 1 or 2 diabetes mellitus (DM) is associated with an increased risk for complications in both the mother and her fetus. The impact of these complications on modifiable risk factors may substantially improve pregnancy outcomes and reduce malformation rates in children. This is a goal of pregravid preparation (PGP) in this category of patients. The review gives the main points of PGP in patients with types 1 and DM and shows the results of main studies providing evidence for PGP in DM. In particular, by the moment of conception, DM patients should achieve a glycosylated hemoglobin (HbA1c) goal of &lt;6% no later than 4 weeks before conception and during the first trimester of pregnancy, take folic acid in a high dose (at least 4000 µg, or 4 mg, daily), quit tobacco smoking and alcohol use, receive potentially teratogenic drugs, and, if need be, lose weight (the target body mass index of &lt;27 kg/m2).</p></abstract><trans-abstract xml:lang="ru"><p>Аннотация Беременность у женщин, больных сахарным диабетом (СД) 1-го типа или 2-го типа, ассоциирована с повышенным риском развития осложнений как у матери, так и плода. Воздействие на модифицируемые факторы риска таких осложнений позволяет существенно улучшить исходы беременности, снизить частоту формирования пороков развития у детей. Это является целью прегравидарной подготовки (ПГП) больных данной категории. В обзоре представлены основные положения ПГП у больных СД 1-го и 2-го типов, отражены результаты основных исследований, обосновывающих проведение ПГП при СД. В частности, к моменту зачатия больным СД рекомендуется достижение целевого уровня гликированного гемоглобина HbA1c &lt;6% не позднее чем за 4 нед до зачатия и на протяжении I триместра беременности, а также прием фолиевой кислоты в высокой дозе (не менее 4000 мкг, или 4 мг, в сутки); отказ от табакокурения, употребления алкоголя, приема потенциально тератогенных препаратов; при необходимости рекомендуется снижение массы тела (целевой индекс массы тела &lt;27 кг/м2).</p></trans-abstract><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>pregravid preparation</kwd><kwd>preconception preparation</kwd><kwd>folic acid</kwd><kwd>folacin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>прегравидарная подготовка</kwd><kwd>преконцепционная подготовка</kwd><kwd>фолиевая кислота</kwd><kwd>фолацин</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. doi:10.1016/j.diabres.2009.10.007</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Shawe J, Smith P, Stephenson J. Use of contraception by women with type 1 or type 2 diabetes mellitus: ‘it’s funny that nobody really spoke to me about it’. Eur J Contracept Reprod Health Care. 2011;16(5):350-358. doi:10.3109/13625187.2011.597896</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Pedersen LM, Tygstrup I, Pedersen J. Congenital malformations in newborn infants of diabetic women. Correlation with maternal diabetic vascular complications. Lancet. 1964;1(7343):1124-1126. doi:10.1097/00006254-196410000-00018</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMCPregnancy and Childbirth. 2006;6:30. doi:10.1186/1471-2393-6-30</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30(7):1920-1925. doi:10.2337/dc07-0278</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Fuhrmann K, Reiher H, Semmler K. Prevention of malformations in infants of insulin-dependent diabetic mothers. Diabetes Care. 1983;6(3):219-223. doi:10.2337/diacare.6.3.219</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M. Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconceptional diabetic control: A comparative study. Am J Obstet Gynaecol. 1986;155(2):293-297. doi:10.1016/0020-7292(87)90271-2</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mills JL, Knopp RH, Simpson JL, Jovanovic-Peterson L, Metzger BE, Holmes LB, Aarons JH, Brown Z, Reed GF, Bieber FR. Lack of relation of increased malformation rates in infants of diabetic mothers to glycaemic control during organogenesis. N Engl J Med. 1988;318(11):671-676. doi:10.1016/0020-7292(89)90576-6</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Pre-conception care of diabetes: glycaemic control prevents congenital anomalies. JAMA. 1991;265(6):731-736. doi:10.1001/jama.265.6.731</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ. 1990;301(6760):1070-1074. doi:10.1136/bmj.301.6760.1070</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA. Pre-conception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet Gynecol. 1991;77(6):846-849. doi:10.1016/0020-7292(92)90749-9</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Willhoite MB, Bennert HW Jr, Palomaki GE, Zaremba MM, Herman WH, Williams JR, Spear NH. The impact of preconception counseling on pregnancy outcomes. The experience of the Maine Diabetes in Pregnancy Program. Diabetes Care. 1993;16(2):450-455. doi:10.2337/diacare.16.2.450</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cousins L. California diabetes and pregnancy Programme: a statewide collaborative program for the pre-conception and prenatal care of diabetic women. Baillieres Clin Obstet Gynaecol. 1991;5(2):443-459. doi:10.1016/s0950-3552(05)80106-3</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care. 2006;29(8):1744-1749. doi:10.2337/dc05-2265</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ, Soo SC, Kelly S, Lim B, Randall J, Thompsett S, Temple RC. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control. Diabetes Care. 2010;33(12):2514-2520. doi:10.2337/dc10-1113</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>NICE guideline 63: diabetes in pregnancy. Management of diabetes and its complications in pregnancy from the pre-conception to the postnatal period (last update 2015). Accessed May 24, 2016. Available at: https://www.nice.org.uk/guidance/ng3</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ, Soo SC, Kelly S, Lim B, Randall J, Thompsett S, Temple RC. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control. Diabetes Care. 2010;33(12):2514-2520. doi:10.2337/dc10-1113</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832-1835. doi:10.1097/00006254-199306000-00005</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Кузнецова И.В., Коновалов В.А. Применение фолиевой кислоты в процессе прегравидарной подготовки и во время беременности. Российский вестник акушера-гинеколога. 2015;15(1):24-31.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Oyama K. Folic acid prevents congenital malformations in the offspring of diabetic mice. Endocr J. 2009;56(1):29-37. doi:10.1507/endocrj.K08E-180</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with Type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22(12):1774-1777. doi:10.1111/j.1464-5491.2005.01784.x</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Figo Working Group On Best Practice In Maternal-Fetal Medicine. Best practice in maternal-fetal medicine. Int J Gynaecol Obstet. 2015;128(1):80-82. doi:10.1016/j.ijgo.2014.10.011</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Гродницкая Е.Э. Фолацин в профилактике дефектов нервной трубки. Журнал акушерства и женских болезней. 2010;LIX(3):87-91.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Richard KM, Peters P. Vitamins, minerals and trace elements. Folic acid. In: Schaefer C, Peters P, Miller RK, eds. Drugs During Pregnancy And Lactation: Treatment Options And Risk Assessment. (Third Edition). Academic Press; 2015.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Плужникова Т.А. Опыт применения фолацина у женщин с репродуктивными потерями и гипергомоцистеинемией. Проблемы репродукции. 2008;2:77-79.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Инструкция по медицинскому применению лекарственного препарата Фолацин, АО «Ядран» Галенский Лабораторий (Хорватия), регистрационное удостоверение №ЛС-001513 от 10.08.2010. Ссылка активна на 24.05.2016. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=86760&amp;t=</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Temple R. Preconception care for women with diabetes: is it effective and who should provide it? Best Pract Res Clin Obstet Gynaecol. 2011;25(1):3-14. doi:10.1016/j.bpobgyn.2010.10.001</mixed-citation></ref></ref-list></back></article>
